Ayvakit (Avapritinib) Patent Expiration, LOE Window & CMS Spending
Ayvakit (Avapritinib) by Blueprint Medicines: FDA Orange Book core substance LOE 2040-04-10 (last listed 2042-03-08), 0 AB generics, $186.9M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Blueprint Medicines |
| FDA Application & Pathway | N212608 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2040-04-10 |
| Last Listed Patent or Exclusivity Date | 2042-03-08 |
| Orange Book Patents (*PED Extensions) | 8 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $186.9M |
| 2024 Medicare Part D Spend | $160.0M |
| 2024 Medicaid Spend | $26.9M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |